AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01587313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide dinitrate / hydralazine capsules
Description: Group 1: Day 1:Two SR capsules; Day 8: One IR capsule Group 2: Day 1:Two SR capsules; Day 8: One IR capsule Group 3: Day 1:Two SR capsules; Day 8: One IR capsule Group 4: Day 1:One IR capsule and two SR capsules; Day 8: Commercial BiDil Tablet tid
Study NCT00596635 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Once Daily Cranberry Capsule
Description: 650mg capsule pure cranberry powder
Study NCT00596635 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Twice Daily Cranberry Capsules
Description: One 650mg cranberry capsule administered twice per day
Study NCT03622450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistin
Description: Polymyxins are bactericidal drugs that bind to lipopolysaccharides (LPS) and phospholipids in the outer cell membrane of gram-negative bacteria.
Study NCT03622450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbapenem + Aminoglycoside/ Quinolone
Description: Dual antipseudomonal given as IV for ventilator associated pneumonia for patients with Multi-drug resistant bacteria risk factors
Study NCT02270268 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pectin
Description: Pectin （Andeli Ltd. Yantai, China）, 24g/d for six weeks
Study NCT02270268 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin
Study NCT02338180 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: proximal preventive sealants
Description: On sound mesial surfaces of first permanent molars adjacent to a caries active lesion of second primary molar, after 4-6 days with an orthodontic separating rubber ring around the approximal contact area. The test site was isolated with cotton rolls or a rubber dam. The surface of 6m was etched with 35% phosphoric acid for 20 sec, washed with water and then air-dried. The sealant (Concise Sealant; 3M ESPE) was applied and light-cured for 20 sec each on the occlusal, buccal and lingual sides. After polymerization, the sealant was inspected for complete coverage.
Study NCT03088059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Afatinib 40 mg given orally, once daily, 1 cycle is 28 days
Study NCT03088059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib 125 mg given orally, once daily, 1 cycle is 28 days (21 days on treatment, then 7 days off)
Study NCT03088059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard of care
Description: Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care
Study NCT03088059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPH2201
Description: protocol v2.0 and 2.1 : Monalizumab 10mg/kg given intravenously over 60 minutes, once every 14 days, 1 cycle is 14 days protocol v4.0 : Monalizumab 750mg given intravenously over 60 minutes, once every 28 days, 1 cycle is 28 days
Study NCT03088059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500mg given intravenously over 60 minutes, once every 28 days, 1 cycle is 28 days
Study NCT03088059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib 300 mg given orally, once daily, 1 cycle is 28 days
Study NCT03088059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: INCAGN01876 300 mg given intravenously over 30 minutes, once every 14 days, 1 cycle is 28 days
Study NCT02338180 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: proximal therapeutic sealant
Description: On mesial surfaces of first permanent molars with caries active lesion adjacent to a caries active lesion of second primary molar , after 4-6 days with an orthodontic separating rubber ring around the approximal contact area. The test site was isolated with cotton rolls or a rubber dam. The surface of 6m was etched with 35% phosphoric acid for 20 sec, washed with water and then air-dried. The sealant (Concise Sealant; 3M ESPE) was applied and light-cured for 20 sec each on the occlusal, buccal and lingual sides. After polymerization, the sealant was inspected for complete coverage.
Study NCT02223676 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical pharmacists conduct medication history
Description: pharmacists conduct medication history before the physician interviews the patient and does not spend time on conducting medical history
Study NCT01969370 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Option to request non-medically actionable incidental information (after receiving education about them)
Study NCT02225418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Study NCT02225418 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: saline
Study NCT04015362 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sub-threshold intermittent pulsed magnetic stimulation
Description: Application of sub-threshold intermittent pulsed magnetic stimulation to spinal cord
Study NCT04015362 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Application of sham magnetic stimulation to spinal cord
Study NCT02159638 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Guardian Enlite sensor
Description: Sensor insertion
Study NCT02159638 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Dexcom G4 platinum sensor
Description: Sensor insertion
Study NCT02997163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Daily oral doses of talazoparib 0.5 mg
Study NCT03604003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: potassium losartan
Description: treated with bedtime or awakening doses of potassium losartan
Study NCT02337764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVP-1012 1mg
Description: TVP-1012 1mg Tablets
Study NCT04172233 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK101
Description: AK101 is an anti-IL-12/23p40 monoclonal antibody.
Study NCT04172233 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: AK101
Description: AK101 is an anti-IL-12/23p40 monoclonal antibody.
Study NCT04172233 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo
Study NCT01800253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inhibitory task
Description: Participants perform a binary decision on each presented stimuli. Of the two possible outcomes, participants are instructed to make a motor response (go) for one type, and are to withhold a response (no-go) for the other type. Reaction time and accuracy are measured for each event
Study NCT01800253 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Hormone levels, neuromolecular levels and gene expression profiles will be analyzed from repeated blood samples obtained before and after the nighttime intervention
Study NCT01800253 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue samples
Description: Expression profiles will be analyzed from samples obtained from tissues involved in metabolism
Study NCT01800253 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test
Description: 75 g of glucose will be dissolved in 300 ml of water and given to participants, followed by blood sampling at 0, 15, 30, 60, 90, 120 and 150 minutes following the ingestion of the glucose solution.
Study NCT01800253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Portion Size Task
Description: Participants are given a computer program that gives them the opportunity to choose the portions of a variety of food items that they would ideally like to consume
Study NCT04292236 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lauric Acid, Perilla Oil and Diindolylmethane
Description: Colonic release capsules containing lauric acid (2400mg), perilla oil (2100mg) and diinodlylmethane (500mg) given to volunteers 1 hour prior to standardised breakfast and lunch meal. Placebo group given cellulose capsules of same volume prior to standardised breakfast and lunch meal.
Study NCT04292236 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lauric Acid, Perilla Oil and Diindolylmethane
Description: Colonic release capsules containing lauric acid (2400mg), perilla oil (2100mg) and diinodlylmethane (500mg) given to volunteers 1 hour prior to standardised breakfast and lunch meal. Placebo group given cellulose capsules of same volume prior to standardised breakfast and lunch meal.
Study NCT00754741 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adherence information
Description: Physicians, of the patients randomized to this arm, will have medication adherence information displayed when using the electronic prescribing system.
Study NCT00754741 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adherence information plus motivational interviewing
Description: Physicians, of the patients randomized to this arm, will have medication adherence information displayed when using the electronic prescribing system. Moreover, patients randomized to this arm will be recruited into a clinic run by pharmacists and nurses with delegated prescription power. The clinic personnel will use motivational interviewing techniques with patients to improve adherence to medications and/or to intensify medical treatment if adherence is optimal.
Study NCT03042546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Sulfate
Description: Calcium Sulfate with abx will be used in the defect
Study NCT03042546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PMMA
Description: PMMA with abx will be used in the defect
Study NCT03042546 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No treatment
Description: The defect will not be treated
Study NCT02576600 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videopupillometer Algiscan
Description: pupillary diameter measurement every five minutes per-operatively
Study NCT02576600 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard practice
Description: remifentanil administration left to the discretion of the anesthesiologist in charge according to standard practice
Study NCT02576600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: TCI
Study NCT02948673 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glutathione
Description: 4 oral GSH tablets/day (1000mg/day) for 4 weeks
Study NCT02948673 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 oral placebo tablets for 4 weeks
Study NCT04542889 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Absolute coronary flow and resistance measurements
Description: Thermodilution-based measurements of absolute coronary resistances using the FFR pressure guide (PressureWire® Certus® from St Jude Medical Abbott) and the Rayflow® microcatheter (Hexacath, Paris, France).
Study NCT04542889 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: IMR measurement
Description: IMR measurement by thermodilution using the St Jude pressure guide.
Study NCT03293004 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolyzed collagen
Description: Escalating dose of Hydrolyzed collagen
Study NCT03293004 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Escalating dose of Vitamin C
Study NCT03293004 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Optimized Hydrolyzed Collagen and Vitamin C
Description: combination of optimized doses of Hydrolyzed Collagen and Vitamin C
Study NCT03293004 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Gummy Placebo
Description: Gummy placebo
Study NCT00477659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil hydrochloride
Description: Donepezil hydrochloride 5 mg per day orally, once daily for 4 weeks, followed by 10 mg per day (two 5-mg tablets) for 8 weeks
Study NCT04059302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Cognitive Behavioral Therapy for Insomnia
Description: The therapy consists of 6 modules or 'cores' that are introduced on a weekly basis. The cores are designed to decrease sleep-inhibiting cognitions and behaviors, and to alter sleep-wake schedules.
Study NCT01967589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0113-0987
Description: Once-daily doses for oral administration. Multiple doses with sequential dose increments over 10 weeks. Progression to next dose increment is based on a safety evaluation
Study NCT01967589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Once-daily doses for oral administration
Study NCT03881176 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PoNS Treatment
Description: The study site will deploy either PoNS Treatment Schedule A or PoNS Treatment Schedule B. Both PoNS Treatment Schedules will consist of three stages: an in-clinic training program, a home training program, and an extended home training program.~During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week. Daily evening sessions and training sessions on weekends will always be performed independently, at-home by the subject
Study NCT03302078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: Fed state
Study NCT03302078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: Fasted state
Study NCT02601976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: PegInterferon alfa-2a 180mcg 20kDa administered subcutaneously once weekly for 24 weeks in genotype 3 and for 48 weeks in genotype 1 patients.
Study NCT02601976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin administered orally in a divided daily dose according to body weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study NCT03472716 — intervention group
Intervention type: PROCEDURE
Intervention: Biological Samples
Description: 5 ml blood sample and one tumoural sample (either a fresh biopsy or the initial diagnosis biopsy).~In case of relapse, new samples will be performed (blood and tumoral samples)
Study NCT04563208 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered on Days 1-5
Study NCT04563208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DuACT
Description: Day1: RBV 600 mg BID and NTZ 500 mg BID Days 2-5: RBV 400 mg BID and NTZ 500 mg BID
Study NCT00876681 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Popliteal catheter placed via ultrasound or electrical stimulation
Description: Patients will be randomized to one of two groups: Popliteal-sciatic catheter placed via ultrasound-guidance or placed via electrical stimulation. All patients will be given 40ml of 1.5% mepivicaine prior to surgery and then given a pain pump after surgery containing 0.2% ropivacaine. The patients pain scores will be assessed just prior to surgery and the day following surgery. The time of catheter placement and numbness the patient is experiencing in their foot and toes is also assessed and recorded by research staff.
Study NCT01131182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin phosphate
Description: Sitagliptin 100 mg tablet administered orally once daily over the Ramadan period.
Study NCT01131182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Sulfonylurea
Description: Sulfonylurea (glibenclamide, glimepiride, or gliclazide) administered orally daily over the Ramadan period as per physician's prescription
Study NCT01131182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants could continue pre-study metformin as concomitant therapy during the study.
Study NCT01131182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Participants could continue pre-study metformin as concomitant therapy during the study.
Study NCT03466073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Plasma Gelsolin
Description: Recombinant human plasma gelsolin lyophilized for reconstitution, reconstituted in sterile water
Study NCT03466073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Saline Placebo
Description: Normal saline in volume equivalent to drug
Study NCT04012476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Administration of 5 mg of intravenous indocyanine green after total thyroidectomy for measurement of parathyroid fluorescence under infrared light
Study NCT00744757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine 20 mg per m\^2 will be administered intravenous infusion over 1 hour, once daily for 5 consecutive days of a 28 days cycle up to 8 cycles or continued until disease progression or unacceptable toxicity.
Study NCT02576600 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Propofol
Description: TCI
Study NCT02576600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: TCI
Study NCT02576600 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Remifentanil
Description: TCI
Study NCT02983123 — intervention group
Intervention type: PROCEDURE
Intervention: 1-hour hs-cTnT
Study NCT03889132 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric Surgery
Description: Subjects with obesity (N=60) will be undertaken a hypocaloric diet and a periodic follow up, also 30 of them will undergo bariatric surgery
Study NCT02971826 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REVIVETM SE thrombectomy
Description: Mechanical thrombectomy using the REVIVETM SE device in patient with an ischemic stroke due to an intracranial arterial occlusion
Study NCT04663113 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group/1st group ( standard physiotherapy
Description: It comprised of parameters such as early mobilization and ambulatory training, pulmonary physiotherapy, active and passive normal joint movement exercises.
Study NCT04663113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2nd group- Standard physiotherapy + bicycle ergometer
Description: Standard physiotherapy + bicycle ergometer: In addition to the standard therapy, a bicycle ergometer for 20 minutes 5 days a week will be given.~Patients will turn the pedals of the bicycle while sitting on the edge of the bed.~In this protocol, a portable bicycle with adjustable pedal system, which can be placed on the edge of the bed, will be used.~Ratings of perceived exertion (RPE) will be used to determine the intensity of aerobic activity. According to the RPE, 10-12 strength exercises will be given.
Study NCT04663113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3rd group- Standard physiotherapy + exercise protocol to be developed
Description: Standard physiotherapy + exercise protocol to be developed: In addition to standard therapy, exercise will be given according to the measured basal metabolic rate of the patients.~Portable indirect calorimetry will be used to measure the basal metabolic rates of the patients.~The basal metabolic rates of the patients will be measured before the exercise and aerobic exercise or resistant exercise will be given according to the metabolic state of the patient.~Ratings of perceived exertion (RPE) will be used as the aerobic exercise protocol and a 10-11 strength exercise will be given according to the RPE.~If resistance exercise will be given, the intensity of the exercise (12-14) will be determined according to the RPE. Sandbags attached to the ankle will be used as a resistance exercise and 9 exercises were determined. (Knee extension, knee flexion, trunk flexion, trunk extension, hip extension, hip flexion, hip abduction, shoulder flexion, shoulder abduction
Study NCT02637596 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: After laparotomy, intraoperative IOUS quided RFA of primary tumor was performed.
Study NCT02757196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab plus methylprednisolone
Description: rituximab （1000mg IV day1, week 3, week 17 , and week 19）
Study NCT02757196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: 1mg/kg, oral or IV; begin to reduce at week 4, reduce 8mg every 2 weeks, then another 8 weeks later reduce 2-4mg every 2-4 weeks
Study NCT03344471 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Passation of questionnaires
Description: Specific questionnaires (Perinatal PTSD Questionnaire evaluating the Post-Traumatic Stress Disorder) and (NEO-FFI evaluating personality)
Study NCT03534284 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Once weekly treatment sessions for 6 weeks. The content of each of these sessions will be adapted to include changes in behavior during HD treatments (such as napping) and to help patients better adjust to treatment schedules. The CBT-I sessions will be delivered by a therapist face-to-face with the patient via a fully interactive video telehealth platform.
Study NCT03534284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: trazodone tablet